← Back to Search

Procedure

Robotic Surgery for Testicular Seminoma

N/A

Recruiting

Led By Robert Hamilton, MD

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Lymphadenopathy in the retroperitoneum: at least one lymph node ≤5cm in size (in the transverse plane) detected on contrast CT scan or MRI (CS IIA/B; or active surveillance relapse with CS IIA/B equivalent)

Curative treatment with RPLND is intended

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years after rplnd

Awards & highlights

Study Summary

This trial will investigate whether a minimally invasive surgical approach is safe and effective for treating early stage seminoma.

Who is the study for?

This trial is for men with a specific type of testicular cancer (seminoma) that has spread to nearby lymph nodes but not beyond. They must have had surgery to remove the tumor, no metastasis in the chest, and meet certain criteria regarding tumor markers. It's not for those who've had extensive previous treatments or surgeries, other serious illnesses, or are unsuitable for robotic surgery.Check my eligibility

What is being tested?

The study tests a minimally invasive surgical technique called Robotic Retroperitoneal Lymph Node Dissection (R-RPLND) as an initial treatment option instead of chemotherapy or radiation. The goal is to see if this approach is safe and effective for stage IIA/B seminoma patients.See study design

What are the potential side effects?

While the side effects aren't detailed here, R-RPLND may include typical risks associated with minimally invasive surgery such as infection risk at incision sites, potential injury to surrounding organs or tissues during operation, bleeding complications, and postoperative pain.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a lymph node in my abdomen that is 5cm or smaller, confirmed by a scan.

Select...

I am planning to undergo surgery to remove lymph nodes for cancer treatment.

Select...

My testicular cancer was confirmed by a biopsy and fully removed.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years after rplnd

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years after rplnd

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years after rplnd for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Relapse Free Survival (RFS)

Secondary outcome measures

Cancer-specific survival (CSS)

Complications

Conversion rate to open surgery

+21 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Robotic Retroperitoneal Lymph Node DissectionExperimental Treatment1 Intervention

Robotic retroperitoneal lymph node dissection performed using the DaVinci robotic surgical system.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,474 Previous Clinical Trials

485,017 Total Patients Enrolled

Robert Hamilton, MDPrincipal InvestigatorThe Princess Margaret Cancer Foundation

Media Library

Robotic Retroperitoneal Lymph Node Dissection (RPLND) (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05345158 — N/A

Testicular Seminoma Research Study Groups: Robotic Retroperitoneal Lymph Node Dissection

Testicular Seminoma Clinical Trial 2023: Robotic Retroperitoneal Lymph Node Dissection (RPLND) Highlights & Side Effects. Trial Name: NCT05345158 — N/A

Robotic Retroperitoneal Lymph Node Dissection (RPLND) (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05345158 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there current opportunities to join this research project?

"According to clinicaltrials.gov, the recruitment phase of this medical trial is currently ongoing. It was first listed on May 1st 2022 and underwent its most recent edit on May 16th 2022."

Answered by AI

How many participants are included in this trial at most?

"Affirmative. According to clinicaltrials.gov, this research is currently accepting volunteers and was initially posted on May 1st 2022, with the most recent update occurring on May 16th of the same year. This study requires 25 test subjects to be admitted at a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma

2022. "R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05345158.